{"filings":[{"id":94326,"accession_number":"0001493152-26-016855","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Beyond Air receives Nasdaq delisting notice for bid price non-compliance; hearing requested","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff notified Beyond Air that its common stock failed to maintain minimum $1.00 bid price per Listing Rule 5550(a)(2).","Company timely requested a hearing on April 13, 2026; delisting action is stayed pending written Panel decision.","Hearing before Nasdaq Hearings Panel is scheduled for May 14, 2026.","There is no assurance the Panel will grant continued listing or that Beyond Air can regain compliance within any granted period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94325,"accession_number":"0001493152-26-016172","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Beyond Air receives Nasdaq delisting notice for bid price non-compliance; reverse stock split ineligible for cure period","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Beyond Air on Apr 7, 2026 that it fails Bid Price Rule; stock closed below $1 for 30 consecutive business days through Apr 6.","Company is ineligible for 180-day cure period due to 1-for-20 reverse stock split on July 14, 2025.","Beyond Air intends to request a hearing before Nasdaq Hearings Panel by Apr 14, 2026; request automatically stays delisting.","Common stock (XAIR) will continue trading on Nasdaq pending Panel decision; no assurance of regaining compliance.","Company considering options including another reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94324,"accession_number":"0001493152-26-014676","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Beyond Air CEO Steve Lisi resigns; Robert Goodman appointed CEO effective March 27, 2026","event_type":"leadership","confidence":"high","bullets":["Steve Lisi resigned as CEO and director, effective March 27, 2026; no disagreement with the Company.","Robert Goodman, previously Chief Commercial Officer and director, appointed CEO effective March 27, 2026.","Lisi receives $650,000 severance over 12 months, 12 months of COBRA premiums, and accelerated vesting of all unvested equity.","Goodman has 25+ years in healthcare sales leadership; prior roles include BioTelemetry, Philips, Cardiocore, Thermo Fisher, and Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106605,"accession_number":"0001493152-26-006708","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Beyond Air Q3 revenue up 105% to $2.2M, net loss narrows; FY2026 guidance reaffirmed at $8-10M","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M, up 105% YoY; gross profit $0.3M vs ($0.2M) gross loss prior year.","Net loss $7.3M ($0.85 loss per share) vs $13.0M ($2.96 loss) prior year.","Pro forma cash $22.3M, including Jan PIPE net proceeds of $4.5M; runway into CY2027.","Appointed Dan Moorhead CFO; Bob Carey appointed Board Chairman.","Binding LOI: XTL to acquire 85% of NeuroNOS; Beyond Air to receive up to $32.5M in cash, equity, milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":5772000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106604,"accession_number":"0001493152-26-004741","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Beyond Air stockholders elect directors, ratify auditor, approve equity plan at 2026 annual meeting","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Steven A. Lisi, Robert S. Goodman, Robert F. Carey, Dr. William Forbes, Yoori Lee, Erick J. Lucera.","Ratification of WithumSmith+Brown, PC as independent auditor for FY ending March 31, 2026: 4,086,430 for, 20,603 against, 114,375 abstain.","Eighth Amended and Restated 2013 Equity Incentive Plan approved, adding 850,000 shares for issuance; 1,119,142 for, 884,509 against.","Adjournment proposal not needed as sufficient votes were present to pass other proposals.","Quorum of 52.70% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106603,"accession_number":"0001493152-26-002884","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Beyond Air raises $5M in private placement of stock and warrants at $1.272/unit","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 3,930,818 shares (or pre-funded warrants) and five-year warrants at $1.147 strike.","Rodman & Renshaw acted as exclusive placement agent; proceeds for working capital and general corporate purposes.","Closing expected Jan 16, 2026; resale registration statement to be filed by Feb 4, 2026.","Offering includes 90-day lock-up on further equity issuance and six-month ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106602,"accession_number":"0001493152-26-002292","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XTL to acquire 85% of Beyond Air's NeuroNOS for equity, $1M cash, up to $32.5M milestones","event_type":"m_and_a","confidence":"high","bullets":["XTL acquires 85% of NeuroNOS for 19.9% of XTL's share capital, $1M cash, and up to $32.5M in milestone payments.","NeuroNOS platform targets core autism pathophysiology; two Nobel Laureates join scientific team.","NeuroNOS holds two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma.","Beyond Air becomes significant XTL shareholder, retains 15% of NeuroNOS; deal valued up to $32.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122936,"accession_number":"0001493152-25-029637","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Beyond Air appoints Dan Moorhead as CFO effective Jan 5, 2026; replaces interim CFO Duke Dewrell","event_type":"leadership","confidence":"high","bullets":["Salary set at $325k; eligible for discretionary bonus and equity participation.","Granted inducement stock option for 70,000 shares, vesting 25% on first anniversary and quarterly thereafter.","Moorhead most recently served as CFO of Zynex, Inc. until August 2025; brings 20+ years of finance leadership.","Duke Dewrell, who assumed CFO duties on an interim basis in November 2025, returns to controller role.","Appointment aligns with preparation for LungFit PH second-generation FDA approval and commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122935,"accession_number":"0001493152-25-027289","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Beyond Air appoints Denton Dewrell as principal financial officer and principal accounting officer","event_type":"leadership","confidence":"high","bullets":["Denton Dewrell, age 39, appointed as principal financial officer and accounting officer effective Dec 8, 2025.","He previously served as Global Controller since April 2025 and U.S. Controller from Aug 2024.","Base compensation remains $260,000 per year, participates in equity incentive plans of company and Beyond Cancer.","Mr. Dewrell is a CPA (Florida and Georgia) and holds a Master of Accounting from University of Florida.","Prior experience includes VP Corporate Controller at Updater Inc. and ten years at Ernst & Young LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122934,"accession_number":"0001493152-25-025348","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CFO Doug Larson resigns; interim CFO Duke Drewell appointed","event_type":"leadership","confidence":"high","bullets":["Doug Larson resigns as CFO effective Dec 5, 2025 to pursue another opportunity; no disagreement with company.","Controller Duke Drewell assumes CFO responsibilities on interim basis; permanent successor search launched.","Larson will serve in advisory role through calendar year-end 2025 to ensure smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122933,"accession_number":"0001493152-25-023538","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q2 revenue up 128% to $1.8M; net loss narrows; secures $32M financing","event_type":"earnings","confidence":"high","bullets":["Revenue $1.8M (+128% YoY); net loss ($7.9M) ($1.25/share) vs. ($13.4M) ($5.67/share).","Secured $32M capital ($12M note, 15%, 24-month maturity + $20M equity line); proforma cash $22.9M, runway into 2027.","Appointed Bob Goodman (Board member) as Interim CCO; David Webster departed.","Updated FY2026 revenue guidance to $8-$10M; achieved MDSAP certification; patent allowance for Gen2 LungFit PH.","International distribution network expanded to 35 countries; Phase 1a UNO trial completed with median survival >23 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":3578000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122932,"accession_number":"0001493152-25-020888","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Beyond Air secures up to $32M in financing from Streeterville Capital","event_type":"debt","confidence":"high","bullets":["Issued $12M promissory note with 15% annual interest; net proceeds ~$12M; $6M placed in restricted account.","Enters $20M equity line of credit (ELOC) to sell shares over 24 months; registration statement to be filed.","Amends loan with CEO Steven Lisi and director Robert Carey: additional $2M term loan, warrants at $1.95/share.","Board approves repricing of 726,618 options to $1.95, covering named executives and directors.","Proforma cash, equivalents, restricted cash, marketable securities of $22.9M as of Sept 30, 2025; runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139631,"accession_number":"0001493152-25-012866","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Beyond Air receives ~$3.25M from warrant exercise; issues new warrants for 719,561 shares","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.25M from immediate exercise of 1,439,126 existing warrants at reduced price of $2.21/share.","Issues new warrants to purchase up to 719,561 shares at $2.21, exercisable immediately, five-year term.","Placement agent Laidlaw receives 6.5% fee; net proceeds for clinical programs and working capital.","Closing expected September 9, 2025; resale registration statement to be filed by September 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139630,"accession_number":"0001493152-25-012825","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroNOS (Beyond Air unit) receives FDA Orphan Drug Designation for BA-101 in glioblastoma","event_type":"regulatory","confidence":"high","bullets":["FDA grants Orphan Drug Designation for BA-101, an investigational nNOS inhibitor, for treatment of glioblastoma.","This is NeuroNOS's second orphan drug designation; ODD provides tax credits, fee waivers, and 7-year market exclusivity if approved.","GBM median survival is <12 months; standard of care (surgery, radiation, temozolomide) is not curative.","NeuroNOS CEO cites urgent unmet need and NO modulation strategy; preclinical data showed NOS inhibition reduced GBM cell proliferation.","Company plans to advance BA-101 toward first-in-human studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139629,"accession_number":"0001641172-25-024647","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beyond Air Q1 revenue rises 157% to $1.8M; net loss narrows to $7.7M","event_type":"earnings","confidence":"high","bullets":["Revenue $1.8M vs $0.7M YoY (+157%); gross profit $0.2M vs loss of $0.3M.","Net loss $(7.7)M ($1.53 per share) vs $(12.2)M ($5.32) in prior year.","Reaffirmed FY2026 revenue guidance of $12-$16M.","Cash $6.5M; net cash burn $4.7M in quarter; debt $11.6M.","Awarded Premier, Inc. group purchasing agreement covering >4,350 hospitals."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1760000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139628,"accession_number":"0001641172-25-018520","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Beyond Air announces 1-for-20 reverse stock split to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1-for-20, effective July 14, 2025.","Approved by stockholders on June 20, 2025; filed Certificate of Amendment on July 9, 2025.","Purpose: raise bid price above $1 to meet Nasdaq Listing Rule 5550(a)(2).","No change in authorized shares (500M common, 10M preferred) or par value.","Fractional shares rounded up; no cash in lieu."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157215,"accession_number":"0001641172-25-016406","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beyond Air shareholders approve reverse stock split at up to 1-for-50 ratio","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split ratio between 1-for-10 and 1-for-50, as determined by the Board.","Vote: 41,924,612 for, 6,382,862 against, 169,243 abstain; no broker non-votes.","Board has sole discretion to implement the split within one year of June 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157214,"accession_number":"0001641172-25-015650","cik":1641631,"company_name":"Beyond Air, Inc.","ticker":"XAIR","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Beyond Air Q4/FY2025 revenue $3.7M (+220% YoY); guides FY2026 $12-16M; filed PMA for LungFit PH II","event_type":"earnings","confidence":"high","bullets":["Revenue $3.7M for FY2025, up 220% YoY; net loss $46.6M ($0.69 per share).","Expects Q1 FY2026 revenue at least $1.7M, full FY2026 revenue $12-16M.","Submitted PMA supplement to FDA for next-gen LungFit PH II (smaller, transport-ready).","Appointed Robert Goodman to Board; international distribution covers 2B+ lives.","Cash $6.9M as of Mar 31, 2025; $2M additional debt financing post-quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}